Bleakley Financial Group LLC Acquires 2,482 Shares of Eli Lilly and Company $LLY

Key Points

• Bleakley Financial Group increased its Eli Lilly stake by 6.9% in Q1, buying 2,482 shares and bringing its total position to 38,452 shares valued at about $35.4 million.
• Several major analysts turned more bullish on Lilly, with firms like UBS, JPMorgan, and RBC raising price targets; the consensus rating remains Moderate Buy with an average target of $1,268.78.
• The company continues to post strong fundamentals, reporting Q1 EPS of $8.55 on revenue of $19.8 billion, while also highlighting new Kisunla Alzheimer’s data and a quarterly dividend of $1.73 per share.

Bleakley Financial Group LLC grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 38,452 shares of the company's stock after buying an additional 2,482 shares during the quarter. Bleakley Financial Group LLC's holdings in Eli Lilly and Company were worth $35,367,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Spire Wealth Management raised its stake in Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after buying an additional 592 shares during the period. Coldstream Capital Management Inc. grew its stake in Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock valued at $32,365,000 after acquiring an additional 8,659 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock worth $33,471,000 after acquiring an additional 7,338 shares in the last quarter. Iams Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $754,000. Finally, Militia Capital Partners LP raised its position in shares of Eli Lilly and Company by 333.3% during the third quarter. Militia Capital Partners LP now owns 2,600 shares of the company's stock worth $1,984,000 after purchasing an additional 2,000 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Guggenheim raised its price target on Eli Lilly to $1,273 and reiterated a Buy rating, reinforcing Wall Street’s confidence in the company’s growth outlook. Benzinga
• Positive Sentiment: Eli Lilly is presenting new Kisunla data at the Alzheimer’s Association International Conference, giving investors another potential pipeline catalyst beyond its blockbuster weight-loss drugs. Benzinga
• Positive Sentiment: Commentary around Eli Lilly’s obesity drugs continues to highlight how important the franchise is to revenue, with two products now generating nearly two-thirds of sales — a reminder of the company’s scale and earnings power. The Motley Fool
• Neutral Sentiment: Cathie Wood’s ARK funds added Eli Lilly alongside other large-cap names, which may signal continued institutional interest but is not a direct company-specific catalyst. Yahoo Finance
• Neutral Sentiment: Social-media and trading chatter remains upbeat, with investors citing upgraded targets and biotech momentum, but these comments are sentiment-driven rather than new fundamental disclosures. Quiver Quantitative
• Neutral Sentiment: A 247WallSt piece argues there may be a new under-the-radar catalyst in Eli Lilly’s pipeline, but it is largely speculative and not a confirmed development. 247WallSt

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. UBS Group lifted their price objective on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a "buy" rating in a report on Monday. The Goldman Sachs Group reissued a "buy" rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Tuesday, July 7th. Royal Bank Of Canada lifted their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a research note on Wednesday, July 8th. Finally, Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,268.78.

Eli Lilly and Company Stock Down 0.2%

LLY stock opened at $1,185.71 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.12 trillion, a P/E ratio of 42.12, a P/E/G ratio of 1.47 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The business has a 50-day moving average of $1,103.63 and a 200-day moving average of $1,034.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 35.81 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.